APUS
AMEX · Biotechnology
Apimeds Pharmaceuticals Us I
$6.39
-0.86 (-11.86%)
Open$6.33
Previous Close$7.25
Day High$6.50
Day Low$5.56
52W High$403.10
52W Low—
Volume—
Avg Volume9.04M
Market Cap3.46M
P/E Ratio—
EPS$-36.71
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.55M | 12.01M | 11.14M |
| Net Income | 858.8K | 710.2K | 724.1K |
| Profit Margin | 7.4% | 5.9% | 6.5% |
| EBITDA | 1.04M | 1.13M | 1.04M |
| Free Cash Flow | 935.0K | 714.0K | 1.10M |
| Rev Growth | -8.4% | +17.9% | -7.5% |
| Debt/Equity | 0.40 | 0.38 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |